Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

Published:2022-12-02 Issue:48 Volume:71 Page:1526-1530
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Link-Gelles Ruth,Ciesla Allison Avrich,Fleming-Dutra Katherine E.,Smith Zachary R.,Britton Amadea,Wiegand Ryan E.,Miller Joseph D.,Accorsi Emma K.,Schrag Stephanie J.,Verani Jennifer R.,Shang Nong,Derado Gordana,Pilishvili Tamara

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference7 articles.

1. Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022.;Rosenblum;MMWR Morb Mortal Wkly Rep,2022

2. Community-based testing sites for SARS-CoV-2—United States, March 2020–November 2021.;Miller;MMWR Morb Mortal Wkly Rep,2021

3. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance.;Fleming-Dutra;JAMA,2022

4. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance—VISION Network, 10 states, December 2021–August 2022.;Britton;MMWR Morb Mortal Wkly Rep,2022

5. Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot.;Wang;bioRxiv

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study;Vaccine: X;2024-10

2. COVID-19 Vaccine Hesitancy and Misinformation Endorsement among a Sample of Native Spanish-Speakers in the US: A Cross-Sectional Study;Healthcare;2024-08-05

3. The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies;MedComm;2024-07-29

4. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023;Eurosurveillance;2024-07-11

5. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial;The Lancet Infectious Diseases;2024-07